Trial Profile

Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix); Varicella zoster virus vaccine live
Indications Chickenpox; Measles; Mumps; Rubella
Focus Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
01 Aug 2008 Results reported in the Pediatric Infectious Disease Journal.
06 Feb 2006 Status changed fro recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com